GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/05/24
GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/24
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break SeriesGlobeNewsWire • 07/15/24
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” SegmentGlobeNewsWire • 07/11/24
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care MedicineGlobeNewsWire • 07/02/24
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell ModulatorsGlobeNewsWire • 06/27/24
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsGlobeNewsWire • 05/22/24
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)GlobeNewsWire • 05/21/24
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)GlobeNewsWire • 05/20/24
GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company ShowcaseGlobeNewsWire • 05/14/24
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/24
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on AutoimmunityGlobeNewsWire • 04/29/24
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarGlobeNewsWire • 04/25/24
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea PatentGlobeNewsWire • 04/16/24
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International ConferenceGlobeNewsWire • 04/08/24
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/01/24
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell ModulatorsGlobeNewsWire • 03/14/24
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United KingdomGlobeNewsWire • 03/04/24